“Can a small applied-AI studio commercialize patent-pending biochemical modeling across enough verticals (drug discovery, nutrition, cannabis, mental health) to become an enterprise AI platform?”
StroomAI is an AI research and consulting firm building predictive biochemical models for drug discovery, clinical outcome prediction, and precision nutrition. Founded by Parker Case, the company positions itself around 6-10 patent-pending innovations and delivers vertical AI products (BioPrisma, BFF Cannabis, HygeiaAI, MeridianAI, ModeAI Stylist, TraffickJam) across healthcare, e-commerce personalization, wildlife conservation, and mental health. It is not an embedded finance company — its financial footprint is limited to accepting subscription/enterprise payments via a third-party processor.
Stroom AI was founded by Parker Case and is headquartered in New York, NY, United States.
Get a read on where your own stack stands against Stroom AI and the rest of its category — what they built versus bought, which providers they use, and where the gaps in your own strategy and competitive set actually are.